Cannabis and opioid use disorder study
Part of Mental health clinical trials.
This Phase 1 trial studies cannabis in people with opioid use disorder. The goal is to better understand how it may affect opioid use disorder, while monitoring safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You currently have opioid use disorder
- You must not have a current medical condition that needs ongoing medical treatment
- Be prepared for medical checkups to confirm safety and study suitability
- You may need medication and health review to make sure your conditions don’t require active treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether cannabis can help ease opioid withdrawal and reduce opioid use. Participants will stay at the hospital for about 6 weeks to receive the study treatment and be closely monitored.
This trial tests if adding a specific cannabis product to standard methadone treatment helps people with opioid use disorder. It's for adults over 25 who recently started methadone and have used cannabis before.
This study tests whether a combination of THC and CBD can help people who have both opioid use disorder and chronic low back pain. You would need to be on a stable dose of methadone and have used cannabis at least once in your life.
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
This trial tests whether two cannabis-like medicines, dronabinol and Epidiolex, can help reduce withdrawal symptoms and other discomforts people may feel when they first start taking buprenorphine for opioid use disorder. If you've recently started buprenorphine and still have symptoms, this study might offer extra relief.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.